Anti-Rheumatic Drugs - Suriname

Suriname

in Suriname, a country South_America, is also a part of the Anti-Rheumatic Drugs market.
In 2024, the revenue in this market is projected to reach US$0.65m.
Looking ahead, there is an expected annual growth rate (CAGR 2024-2029) of 2.07%, which will result in a market volume of US$0.72m by 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in this market, with an estimated amount of US$34,700.00m in 2024.
Suriname's market for Anti-Rheumatic Drugs is witnessing a growing demand due to the increasing prevalence of rheumatic diseases in the country.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Suriname has seen significant growth in recent years.

Customer preferences: Customers in Suriname have shown a growing preference for Anti-Rheumatic Drugs due to the rising incidence of rheumatoid arthritis in the country. The aging population in Suriname is also a contributing factor to the increased demand for these drugs.

Trends in the market: The Anti-Rheumatic Drugs market in Suriname is expected to continue its growth trajectory in the coming years. This is due to the increasing prevalence of rheumatoid arthritis in the country, which is expected to drive demand for these drugs. Additionally, the introduction of new and innovative drugs in the market is expected to further boost growth.

Local special circumstances: Suriname has a small population and a relatively underdeveloped healthcare system. This has resulted in limited access to healthcare services, including Anti-Rheumatic Drugs. However, the government has taken steps to improve healthcare services in the country, which is expected to increase access to these drugs.

Underlying macroeconomic factors: Suriname's economy is heavily dependent on the export of natural resources, particularly gold and oil. The country has experienced economic instability in recent years due to fluctuations in commodity prices and political uncertainty. This has had an impact on the healthcare sector, with limited funding available for healthcare services and infrastructure. However, the government has made efforts to improve the healthcare sector in the country, which is expected to benefit the Anti-Rheumatic Drugs market in the long term.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.